Today's TEVA announcement has nothing to do with ATRS. TEVA earns 100% from the Suma patch but they only earn 50% from the ATRS/TEVA injector. I wonder which one TEVA will promote?
I'm surprised the PR didn't say they were also developing a EPI & testosterone patch.
"Otrexup TRx should be 1000+ weekly by the end of the year" How do you figure that?
Bear markets occur with recessions. We need Fed tightening & oil prices moving up to push us into a recession. We've probably got another year before we have to really worry about the markets.
We got the all clear signal today with the GDP numbers. I guess everything is back to normal.
Its hard for me to believe this is the start of another leg up when China, oil, & the Fed are playing on investors minds. Shorts were caught today but the battle is still in the early stages.
Negative sentiment continues to build. Just read where Gartman calls for S&P 1200. He's normally wrong but selling leads to more selling. If ATRS is lucky it might trade at $2 after Epi & Suma approvals,
The guy is a walking disaster. Its like dealing with a kid who rebels when he doesn't get his way.
I imagine this is going to be the trading pattern for awhile.
You need to layoff the end of the world websites or whatever you've been reading.
I thought we might see less volatility Monday but it looks ugly. The best thing would be some panic selling.
I'm on my iPad while watching the Saints. I give it 50% since the epipen requires a higher standard then most applications due to it being a life saving injector. Everything I've seen points to approval but why has the FDA asked TEVA to provide supplements to the original application?
Short-seller who targeted Beverly biotech takes aim at Ocata
Paul Wotton is CEO of Ocata
The second Massachusetts biotech firm in two weeks has become the target of an anonymous short-seller who posts lengthy blogs on a popular investor website apparently seeking to force the stock price down.
An Aug. 6 blog post about Cellceutix, which is traded over-the-counter under the symbol, “CTIX," caused an initial stock drop of 20 percent in the small Beverly-based company (I visited the company last week to talk to the CEO, who said the article is based on “faulty science” and is “grossly illegal.”)
But the blog posted this week by the short-seller, which identifies itself only as Mako Research, was met with an 18 percent stock spike at Ocata Therapeutics (Nasdaq: OCAT), suggesting that investors aren’t buying the arguments presented as to why the Marlborough company shares “are worth nothing,” as the author claims.
I spoke to Ocata CEO Paul Wotton last week and posted a story about the company on Monday, two days before the blog post. He told me about the company’s plans to start a 60 patient mid-stage trial in patients with age-related macular degeneration in the next month and a half. An earlier trial — results of which were published in the medical journal, The Lancet — showed that the transplantation of Ocata’s cells (made from stem cells) into the eyes of 18 patients with macular degeneration stopped the progression of disease in 17 out of 18 patients after six months, and actually helped improve vision in 10 of 18 of those patients.
"So what happens when someone files with FDA do the have a cabinet where they store all the applications"
You do realize the FDA is a government agency? How can you say they actively review applications when it takes them an average of 3 yrs to review an ANDA whereas an NDA has a lot more info & they can do it in a year?
- Funds investment is the strongest indicator - I have no idea why that would give you any confidence since they also invested $50 million in few years ago at $4 & they're down 50% on that decision.
-Mylan expects an EPI competitor - Do you think it would be smarter for Mylan's management to say they think TEVA's injector will be denied?
-There is no legal reason - Nonfactor to the FDA's decision.
-Why would FDA deny after 5 yrs - Just because the FDA's held the application for a long-time doesn't mean they were actively reviewing it.
I give approval a 50/50 chance.
I've only known there was a problem for a few weeks & I had to order a computer to get Windows 10.